Development and Evaluation of 5-Flucytosine Solid Lipid Nanoparticle-Loaded Topical Gels for Enhanced Chronic Wound Healing

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Innovation Pub Date : 2025-08-02 DOI:10.1007/s12247-025-10063-y

Vinay Kumar Chakravarthy Maddikunta, Kumaraswamy Gandla, Rajkumari Thagele

{"title":"Development and Evaluation of 5-Flucytosine Solid Lipid Nanoparticle-Loaded Topical Gels for Enhanced Chronic Wound Healing","authors":"Vinay Kumar Chakravarthy Maddikunta, Kumaraswamy Gandla, Rajkumari Thagele","doi":"10.1007/s12247-025-10063-y","DOIUrl":null,"url":null,"abstract":"<div><p>This study aimed to develop and evaluate a 5-Flucytosine (5-FC)-loaded solid lipid nanoparticle (SLN) gel optimized for chronic wound healing. SLNs were prepared using stearic acid and poloxamer 407 and optimized via central composite design. The optimized nanoparticles exhibited a particle size of 390.60 nm, entrapment efficiency of 89.60% and PDI of 0.215. SLNs were incorporated into a Carbopol 934 gel base for topical application. The formulation demonstrated a high drug content (94.58 ± 0.73% w/w) and favorable rheological properties. In vitro drug release studies indicated an initial burst followed by sustained release (91.5% at 7 h). FTIR confirmed drug-excipient compatibility. Biocompatibility was verified using an MTT assay in human fibroblasts. In vivo wound healing studies in diabetic mice showed enhanced collagen deposition, immune cell recruitment, and accelerated wound closure. The developed SLN-based gel presents a promising strategy for localized, sustained antimicrobial delivery in chronic wound management.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10063-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to develop and evaluate a 5-Flucytosine (5-FC)-loaded solid lipid nanoparticle (SLN) gel optimized for chronic wound healing. SLNs were prepared using stearic acid and poloxamer 407 and optimized via central composite design. The optimized nanoparticles exhibited a particle size of 390.60 nm, entrapment efficiency of 89.60% and PDI of 0.215. SLNs were incorporated into a Carbopol 934 gel base for topical application. The formulation demonstrated a high drug content (94.58 ± 0.73% w/w) and favorable rheological properties. In vitro drug release studies indicated an initial burst followed by sustained release (91.5% at 7 h). FTIR confirmed drug-excipient compatibility. Biocompatibility was verified using an MTT assay in human fibroblasts. In vivo wound healing studies in diabetic mice showed enhanced collagen deposition, immune cell recruitment, and accelerated wound closure. The developed SLN-based gel presents a promising strategy for localized, sustained antimicrobial delivery in chronic wound management.

Abstract Image

查看原文本刊更多论文

5-氟胞嘧啶固体脂质纳米颗粒外用凝胶促进慢性伤口愈合的开发和评价

本研究旨在开发和评估一种负载5-氟胞嘧啶（5-FC）的固体脂质纳米颗粒（SLN）凝胶，优化其用于慢性伤口愈合。以硬脂酸和poloxamer 407为原料制备了sln，并通过中心复合设计对其进行了优化。优化后的纳米颗粒粒径为390.60 nm，包封效率为89.60%，PDI为0.215。将sln掺入Carbopol 934凝胶基中局部应用。该制剂具有较高的药物含量（94.58±0.73% w/w）和良好的流变性能。体外药物释放研究表明，最初的爆发随后是持续释放（7h时91.5%）。FTIR证实了药物-赋形剂的相容性。在人成纤维细胞中使用MTT试验验证生物相容性。糖尿病小鼠的体内伤口愈合研究显示胶原沉积增强，免疫细胞募集，伤口愈合加速。开发的基于sln的凝胶在慢性伤口管理中提供了一种有前途的局部，持续的抗菌药物递送策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-

CiteScore

3.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.